While TP53 mutations in 23% of patients by DNA-sequencing did not show a significant prognostic effect, simultaneous RNA-seq detected TP53 variants in 38.8% of patients and associated with elevated chromosomal CNVs, and those with ≥ 40% VAFs demonstrated remarkably adverse prognostic effects in patients with PT-DLBCL. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.